Hope for CKD-MBD Patients: New Diagnostic Approaches for Better Treatment of CKD-MBD

被引：10

作者：

Hocher, Berthold ^{[1
,2
,3
,4
]}

Pasch, Andreas ^{[5
]}

机构：

[1] Univ Potsdam, Inst Nutr Sci, Potsdam, Germany

[2] Inst Lab Med Berlin, IFLb, Berlin, Germany

[3] Jinan Univ, Dept Embryol, Sch Med, Guangzhou, Guangdong, Peoples R China

[4] Jinan Univ, Dept Nephrol, Guangzhou Overseas Chinese Hosp, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China

[5] Univ Bern, Dept Clin Res, Univ Hosp Bern, Bern, Switzerland

来源：

KIDNEY DISEASES | 2017年 / 3卷 / 01期

关键词：

Biomarker; Calcification propensity; Chronic kidney disease-mineral and bone disorder; Nonoxidized parathyroid hormone; Morbidity; Mortality; T-50; test; SERUM CALCIFICATION PROPENSITY; HUMAN PARATHYROID-HORMONE; CHRONIC KIDNEY-DISEASE; INDEPENDENT RISK-FACTOR; CHRONIC-RENAL-FAILURE; ALL-CAUSE MORTALITY; HEMODIALYSIS-PATIENTS; CARDIOVASCULAR-DISEASE; TRANSPLANT RECIPIENTS; BIOLOGICAL-ACTIVITY;

D O I：

10.1159/000477244

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

100201 [内科学]; 100221 [泌尿外科学];

摘要：

Background: Chronic kidney disease-mineral and bone disorder (CKD-MBD) patients have a huge morbidity and mortality. Only relatively minor progress in therapeutic strategies has been made in the past decades. This is at least partially due to a lack of predictive diagnostic tools allowing personalized treatment of CKD-MBD patients. Summary: In this review we describe recent progress in the diagnosis of disturbances of calcium and phosphate metabolism in patients with CKD-MBD, measuring biological active nonoxidized parathyroid hormone as well as the overall likelihood of a patient to get calcified. Key Message: There is hope. The new tools have the potential of allowing personalized therapy for the treatment of CKD-MBD and hence improving outcome. (c) 2017 S. Karger AG, Basel

引用

页码：8 / 14

页数：7

共 70 条

[1]

Calcification of vascular smooth muscle cells is induced by secondary calciprotein particles and enhanced by tumor necrosis factor-α [J].